Immunitybio Stock Working Capital

IBRX Stock

USD 5.04 0.06 1.18%

Immunitybio fundamentals help investors to digest information that contributes to Immunitybio's financial success or failures. It also enables traders to predict the movement of Immunitybio Stock. The fundamental analysis module provides a way to measure Immunitybio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunitybio stock.

	Last Reported	Projected for Next Year
Net Working Capital	235.8 M	247.6 M
Change In Working Capital	4 M	3.4 M

Net Working Capital is likely to rise to about 247.6 M in 2024, whereas Change In Working Capital is likely to drop slightly above 3.4 M in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Immunitybio Company Working Capital Analysis

Immunitybio's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Immunitybio Working Capital

235.8 M

Most of Immunitybio's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunitybio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Immunitybio Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Immunitybio is extremely important. It helps to project a fair market value of Immunitybio Stock properly, considering its historical fundamentals such as Working Capital. Since Immunitybio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunitybio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunitybio's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Term Investments	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Net Invested Capital	Long Term Investments	Capital Stock	Net Working Capital	Deferred Long Term Liab	Short Long Term Debt
Total Assets		-0.38	-0.82	0.61	-0.75	0.64	0.23	0.68	0.95	0.45	0.57	0.7	-0.31	0.73	0.65	-0.64	0.53	0.41	-0.7	0.55	-0.03	-0.33	0.56
Total Stockholder Equity	-0.38		0.28	-0.91	0.86	-0.64	0.03	-0.92	-0.24	-0.44	-0.64	-0.87	0.7	-0.83	-0.85	0.91	-0.67	-0.28	0.87	-0.75	-0.06	0.68	-0.82
Current Deferred Revenue	-0.82	0.28		-0.53	0.72	-0.6	-0.45	-0.57	-0.69	-0.32	-0.57	-0.65	0.52	-0.58	-0.56	0.58	-0.32	-0.27	0.51	-0.36	0.02	0.32	-0.41
Net Debt	0.61	-0.91	-0.53		-0.93	0.86	0.04	0.93	0.44	0.68	0.66	0.89	-0.62	0.91	0.86	-0.95	0.51	0.53	-0.94	0.61	-0.19	-0.53	0.76
Retained Earnings	-0.75	0.86	0.72	-0.93		-0.78	-0.17	-0.97	-0.6	-0.47	-0.75	-0.98	0.73	-0.91	-0.91	0.96	-0.68	-0.35	0.91	-0.75	-0.05	0.67	-0.82
Accounts Payable	0.64	-0.64	-0.6	0.86	-0.78		0.05	0.71	0.45	0.81	0.56	0.69	-0.5	0.85	0.68	-0.83	0.21	0.52	-0.73	0.32	-0.54	-0.15	0.59
Net Receivables	0.23	0.03	-0.45	0.04	-0.17	0.05		0.09	0.16	-0.05	0.01	0.12	-0.26	0.07	0.1	-0.05	0.11	-0.08	-0.04	0.12	0.09	-0.1	0.1
Total Liab	0.68	-0.92	-0.57	0.93	-0.97	0.71	0.09		0.56	0.46	0.75	0.98	-0.68	0.88	0.94	-0.95	0.72	0.36	-0.95	0.79	0.1	-0.75	0.85
Total Current Assets	0.95	-0.24	-0.69	0.44	-0.6	0.45	0.16	0.56		0.33	0.4	0.58	-0.09	0.58	0.5	-0.46	0.49	0.43	-0.59	0.47	0.09	-0.29	0.4
Short Term Debt	0.45	-0.44	-0.32	0.68	-0.47	0.81	-0.05	0.46	0.33		0.36	0.35	-0.21	0.6	0.43	-0.57	-0.09	0.8	-0.65	0.01	-0.79	0.13	0.32
Intangible Assets	0.57	-0.64	-0.57	0.66	-0.75	0.56	0.01	0.75	0.4	0.36		0.72	-0.76	0.62	0.81	-0.82	0.54	0.02	-0.71	0.66	-0.05	-0.62	0.84
Common Stock	0.7	-0.87	-0.65	0.89	-0.98	0.69	0.12	0.98	0.58	0.35	0.72		-0.7	0.87	0.9	-0.93	0.73	0.28	-0.88	0.79	0.2	-0.77	0.81
Short Term Investments	-0.31	0.7	0.52	-0.62	0.73	-0.5	-0.26	-0.68	-0.09	-0.21	-0.76	-0.7		-0.61	-0.72	0.76	-0.51	0.09	0.56	-0.61	-0.04	0.58	-0.74
Capital Surpluse	0.73	-0.83	-0.58	0.91	-0.91	0.85	0.07	0.88	0.58	0.6	0.62	0.87	-0.61		0.79	-0.92	0.65	0.41	-0.86	0.7	-0.14	-0.38	0.79
Property Plant Equipment	0.65	-0.85	-0.56	0.86	-0.91	0.68	0.1	0.94	0.5	0.43	0.81	0.9	-0.72	0.79		-0.91	0.7	0.25	-0.91	0.79	0.07	-0.75	0.89
Net Tangible Assets	-0.64	0.91	0.58	-0.95	0.96	-0.83	-0.05	-0.95	-0.46	-0.57	-0.82	-0.93	0.76	-0.92	-0.91		-0.6	-0.32	0.91	-0.71	0.11	0.62	-0.87
Long Term Debt	0.53	-0.67	-0.32	0.51	-0.68	0.21	0.11	0.72	0.49	-0.09	0.54	0.73	-0.51	0.65	0.7	-0.6		-0.14	-0.62	0.98	0.56	-0.68	0.8
Net Invested Capital	0.41	-0.28	-0.27	0.53	-0.35	0.52	-0.08	0.36	0.43	0.8	0.02	0.28	0.09	0.41	0.25	-0.32	-0.14		-0.56	-0.13	-0.46	0.09	-0.03
Long Term Investments	-0.7	0.87	0.51	-0.94	0.91	-0.73	-0.04	-0.95	-0.59	-0.65	-0.71	-0.88	0.56	-0.86	-0.91	0.91	-0.62	-0.56		-0.7	0.08	0.61	-0.79
Capital Stock	0.55	-0.75	-0.36	0.61	-0.75	0.32	0.12	0.79	0.47	0.01	0.66	0.79	-0.61	0.7	0.79	-0.71	0.98	-0.13	-0.7		0.46	-0.74	0.9
Net Working Capital	-0.03	-0.06	0.02	-0.19	-0.05	-0.54	0.09	0.1	0.09	-0.79	-0.05	0.2	-0.04	-0.14	0.07	0.11	0.56	-0.46	0.08	0.46		-0.59	0.07
Deferred Long Term Liab	-0.33	0.68	0.32	-0.53	0.67	-0.15	-0.1	-0.75	-0.29	0.13	-0.62	-0.77	0.58	-0.38	-0.75	0.62	-0.68	0.09	0.61	-0.74	-0.59		-0.65
Short Long Term Debt	0.56	-0.82	-0.41	0.76	-0.82	0.59	0.1	0.85	0.4	0.32	0.84	0.81	-0.74	0.79	0.89	-0.87	0.8	-0.03	-0.79	0.9	0.07	-0.65

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Immunitybio

Working Capital Over Time

Immunitybio Capital Surpluse

Capital Surpluse

1.27 Billion

At this time, Immunitybio's Capital Surpluse is fairly stable compared to the past year.

According to the company's disclosures, Immunitybio has a Working Capital of 235.8 M. This is 44.6% lower than that of the Biotechnology sector and 56.22% lower than that of the Health Care industry. The working capital for all United States stocks is 84.05% higher than that of the company.

Immunitybio Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunitybio's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunitybio could also be used in its relative valuation, which is a method of valuing Immunitybio by comparing valuation metrics of similar companies.

Immunitybio is currently under evaluation in working capital category among its peers.

Immunitybio Current Valuation Drivers

We derive many important indicators used in calculating different scores of Immunitybio from analyzing Immunitybio's financial statements. These drivers represent accounts that assess Immunitybio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunitybio's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	1.5B	5.1B	2.4B	2.0B	2.6B	2.7B
Enterprise Value	1.5B	5.3B	2.8B	2.6B	3.0B	2.8B

Immunitybio ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunitybio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunitybio's managers, analysts, and investors.

Environmental

Governance

Social

Immunitybio Fundamentals

	Return On Asset	-0.56
	Operating Margin	(13.14) %
	Current Valuation	4.17 B
	Shares Outstanding	696.83 M
	Shares Owned By Insiders	77.00 %
	Shares Owned By Institutions	10.11 %
	Number Of Shares Shorted	52.05 M
	Price To Sales	484.70 X
	Revenue	622 K
	Gross Profit	240 K
	EBITDA	(436.18 M)
	Net Income	(583.2 M)
	Cash And Equivalents	82.94 M
	Cash Per Share	0.21 X
	Total Debt	726.72 M
	Current Ratio	0.31 X
	Book Value Per Share	(1.07) X
	Cash Flow From Operations	(366.76 M)
	Short Ratio	5.76 X
	Earnings Per Share	(0.90) X
	Price To Earnings To Growth	3.69 X
	Target Price	14.25
	Number Of Employees	672
	Beta	-0.43
	Market Capitalization	3.55 B
	Total Asset	504.45 M
	Retained Earnings	(2.96 B)
	Working Capital	235.8 M
	Net Asset	504.45 M

About Immunitybio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immunitybio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunitybio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunitybio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC